Oncolytics Biotech Inc. Common Stock (ONCY)
Stock · NASDAQ · Health Care
$0.5as of 10/16/2026
Price chart
Active signals
ONCY Signal Track Record
How signals performed across all stocks →What ONCY's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 43 | -0.8% | 44% | September 22, 2026 |
| Bollinger Band Breakdown | 25 | +5.3% | 52% | September 10, 2026 |
| Bollinger Band Breakout | 19 | -7.7% | 47% | May 29, 2026 |
| 200-Day Moving Average TouchActive now | 8 | -8.1% | 38% | May 29, 2026 |
| Any 20-session window (baseline) | -4.3% | 38% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ONCY
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply i…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 29
- Website
- www.oncolyticsbiotech.com/
Fundamentals
- 1-day range
- $0.4422$0.56
- Market cap
- $95.55M
- P/E (trailing)
- —
- P/E (forward)
- -2.75
- EPS (trailing)
- $-0.37
- Dividend yield
- —
- Beta
- 0.84
- Avg. volume
- 1.05M
- Dividend pay date
- May 25, 2018
Forecasts
6 analyst ratings
Oncolytics Biotech Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ONCYOncolytics Biotech Inc. Common Stock$0.5▼ 9.09%Market cap $95.55MP/E —$1.48$4.49
- ALDXAldeyra Therapeutics Inc. Common Stock$0.7▼ 5.02%Market cap $95.91MP/E —$0.8619$5.93
- HRTXHeron Therapeutics Inc. Common Stock$0.36▼ 5.26%Market cap $94.45MP/E —$0.261$1.58
- RANIRani Therapeutics Holdings Inc. Class A Common Stock$0.641▼ 5.74%Market cap $96.76MP/E —$0.462$3.87
- VRCAVerrica Pharmaceuticals Inc. Common Stock$3.6▼ 4.89%Market cap $92.08MP/E —$3.28$9.82
- ZYBTZhengye Biotechnology Holding Limited Class A Ordinary Shares$1.4▼ 6.67%Market cap $99.05MP/E —$0.6155$8.01
- FBIOFortress Biotech Inc. Common Stock$1.87▼ 2.09%Market cap $92.02MP/E 0.58$1.88$4.53
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ONCY Oncolytics Biotech Inc. Common Stock | $95.55M | — | $0.5 | ▼ 9.09% | $1.48$4.49 |
| ALDX Aldeyra Therapeutics Inc. Common Stock | $95.91M | — | $0.7 | ▼ 5.02% | $0.8619$5.93 |
| HRTX Heron Therapeutics Inc. Common Stock | $94.45M | — | $0.36 | ▼ 5.26% | $0.261$1.58 |
| RANI Rani Therapeutics Holdings Inc. Class A Common Stock | $96.76M | — | $0.641 | ▼ 5.74% | $0.462$3.87 |
| VRCA Verrica Pharmaceuticals Inc. Common Stock | $92.08M | — | $3.6 | ▼ 4.89% | $3.28$9.82 |
| ZYBT Zhengye Biotechnology Holding Limited Class A Ordinary Shares | $99.05M | — | $1.4 | ▼ 6.67% | $0.6155$8.01 |
| FBIO Fortress Biotech Inc. Common Stock | $92.02M | 0.58 | $1.87 | ▼ 2.09% | $1.88$4.53 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- 3 Clinical-Stage Cancer Stocks With Pristine Balance SheetsYahoo · 9/16/2026
Insider Activity
Insider Actions →- Holtham Angela · June 1, 2026 · Grant30.0K
- James T. Parsons · June 1, 2026 · Grant30.0K
- Andrew Aromando · June 1, 2026 · Grant260.0K
- Jared Kelly · June 1, 2026 · Grant755.0K
- Patricia S. Andrews · June 1, 2026 · Grant30.0K
- Bernd R. Seizinger · June 1, 2026 · Grant30.0K
- Allison Hagerman · June 1, 2026 · Grant260.0K
- Thomas Charles Heineman · June 1, 2026 · Grant260.0K
- Deborah Margaret Brown · June 1, 2026 · Grant30.0K
- RIGBY JONATHAN · June 1, 2026 · Grant30.0K
- Kirk Look · June 1, 2026 · Grant260.0K
- Wayne Pisano · June 1, 2026 · Grant30.0K
- McAdory John Bearden · June 1, 2026 · Grant145.0K
- Stephen C. Glover · June 1, 2026 · Grant96.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 860.0K
- Total value held
- $731.0K
- Institutional holders
- 2
- Unknown859.8K
- Unknown194
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Oncolytics Biotech Activates All REO 033 Trial Facilities
Oncolytics Biotech has activated all planned facilities for Part A of its REO 033 trial in colorectal cancer. The company reported accelerating enrollment, with multiple participants admitted to the study. This progress occurs as the broader KRAS inhibitor market is projected to grow significantly in the coming years.
Oncolytics Biotech Activates All REO 033 Trial Facilities. Oncolytics Biotech has activated all planned facilities for Part A of its REO 033 trial in colorectal cancer. The company reported accelerating enrollment, with multiple participants admitted to the study. This progress occurs as the broader KRAS inhibitor market is projected to grow significantly in the coming years.